--- canonical_name: Solubilized Keratin alternate_names: Cynatine, Cynatine FLX, Cynatine HNS, Solubilised Keratin, Functional Keratin, Wool Keratin Peptides canonical_topic: Solubilized Keratin for Health & Longevity short_topic_lc: solubilized_keratin creation_date: 2026-0813-0815 creator_ai_fullname: Grok 4.5 --- # Solubilized Keratin for Health & Longevity
Evidence Review created on 08/13/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4.5 **Also known as:** Cynatine, Cynatine FLX, Cynatine HNS, Solubilised Keratin, Functional Keratin, Wool Keratin Peptides ## Motivation Solubilized keratin is wool protein processed so it dissolves and can be absorbed. Native keratin, the tough fiber in hair, nails, and the outer skin, is almost useless as food. A patented New Zealand wool process yields small, sulfur-rich protein fragments sold mainly as Cynatine. Longevity-oriented adults use it hoping to support the same structural proteins that thin with age — especially hair, skin, and nails. Wool processors brought the ingredient to market in the mid-2000s as Functional Keratin, first for joints and then for hair, skin, and nails. Small company-funded human trials, plus a later trial of thoroughly broken-down feather keratin, sit beside a much thinner independent literature. Salon “keratin treatments” that use formaldehyde are a different product and are not this intervention. This review examines whether oral solubilized keratin changes hair, skin, or nail quality, how that evidence was produced, what is known about harm, and the practical details of dose, source, and monitoring. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews and primary reports that name solubilized keratin or a closely related oral keratin hydrolysate. - [How Solubilized Keratin Builds Beauty From Within](https://www.lifeextension.com/magazine/2016/2/beauty-from-within-healthy-hair-skin-and-nails) - Marcus Phillips Magazine overview of solubilized wool keratin for hair, skin, and nails, summarizing company data and the Cynatine HNS trials. - [Nail Supplements: When, How, and Why?](https://pubmed.ncbi.nlm.nih.gov/40176998/) - Zaraa & Richert, 2025 Dermatology narrative review that lists solubilized keratin among oral nail ingredients and flags weak regulation of supplement claims. - [Novel keratin ingredient may relieve joint pain and stiffness: RCT data](https://www.nutraingredients.com/Article/2013/09/17/Novel-keratin-ingredient-may-relieve-joint-pain-and-stiffness-RCT-data/) - Stephen Daniells Trade-press walkthrough of the Roxlor-funded Cynatine FLX knee trial, including the early pain signal and the large placebo response. - [A clinical trial to investigate the effect of Cynatine HNS on hair and nail parameters](https://pubmed.ncbi.nlm.nih.gov/25386609/) - Beer et al., 2014 Primary 90-day randomized trial of Cynatine HNS on hair-pull, growth-phase ratio, tensile strength, and nail breakage. Roxlor LLC funded the trial and employed a co-author. - [The Effects of an Oral Supplementation of a Natural Keratin Hydrolysate on Skin Aging](https://pubmed.ncbi.nlm.nih.gov/39367631/) - Tursi et al., 2025 BCF Life Sciences–supported randomized trial of a poultry-feather keratin hydrolysate given alone, useful for comparing that free-amino-acid form with wool-derived solubilized keratin. Dedicated commentary from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Lifespan.io was not found. Those sources discuss collagen, biotin, or keratin as the hair protein, not oral solubilized keratin. ## Grokipedia No dedicated Grokipedia article for solubilized keratin as a health intervention was found as of 13 August 2026. ## Examine - [Keratin](https://examine.com/supplements/keratin/) Examine’s keratin supplement page, last updated 5 May 2026, with a research feed that includes oral keratin-hydrolysate trials. ## ConsumerLab No ConsumerLab article for solubilized keratin was found as of 13 August 2026. ## Systematic Reviews PubMed returns one systematic review that includes a solubilized-keratin product among other hair nutraceuticals, with no keratin-only review and none on principal risks. - [Evaluating the Effectiveness of Commercial Oral Supplements for Hair Growth: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/41954038/) - Alanazi et al., 2026 Pooled 14 hair-nutraceutical trials including Cynatine HNS; industry funding is common and keratin-only effects are not isolated. No systematic review of adverse effects, allergenicity, or long-term safety of solubilized keratin was found on PubMed as of 13 August 2026. That risk side of the trade-off is unrepresented. ## Mechanism of Action Solubilized keratin is wool protein processed so it dissolves in water and can be digested. Native keratin is almost unavailable as food because disulfide bonds resist human enzymes. The patented wool process used for Cynatine keeps more of the cysteine-rich peptide structure than harsh hydrolysis, then yields oligopeptides (short protein fragments) the gut can absorb. A related feather hydrolysate (Kera-Diet) is broken into free amino acids. Two accounts compete. The building-block account says cysteine and other residues are reused to make hair, nail, and epidermal keratin, and [Beer’s trial](https://pubmed.ncbi.nlm.nih.gov/25386609/) found higher cystine and related amino acids in hair after 90 days. The signaling account says circulating amino acids and small peptides prompt dermal fibroblasts (the skin cells that build the dermis) to make glycosaminoglycans (skin-matrix sugars) and hyaluronan (hyaluronic acid) and to resist oxidative stress. A third account is antioxidant: cysteine can feed glutathione (the cell’s main sulfur antioxidant), and early animal work reported higher activity of glutathione peroxidase (an enzyme that uses glutathione to neutralize peroxides) and superoxide dismutase (an enzyme that clears superoxide radicals). For joints, manufacturers claim keratin peptides support proteoglycan (joint-cushioning sugar-protein) synthesis and blunt inflammatory signaling; human proof is limited to symptom scores. Pharmacology is that of a food protein, not a receptor drug. After a 5 g hydrolysate dose, plasma amino acids peaked at about 20 minutes. Half-life of intact Cynatine peptides in humans is not published. There is no cytochrome-mediated metabolism. Tissue selectivity beyond the measured change in hair amino acids is unpublished. ## Historical Context & Evolution Keratin entered cosmetics as a topical protein long before it was sold as a food. Wool chemists in New Zealand (Keratec, later Keraplast) patented a method in the 2000s to recover soluble, bioactive wool proteins without destroying cystine. The first commercial nutraceutical, Cynatine FLX, was launched around 2005 as a joint ingredient. A hair-skin-nail version, Cynatine HNS, followed and was combined with zinc, copper, biotin, and B vitamins. Three manufacturer-supported randomized trials appeared in 2013–2014, all with Christina Beer, Simon Wood, and Roxlor’s Robert Veghte as authors: one on [knee osteoarthritis](https://pubmed.ncbi.nlm.nih.gov/23927594/) with keratin alone, and two on [skin](https://pubmed.ncbi.nlm.nih.gov/23902431/), [hair, and nails](https://pubmed.ncbi.nlm.nih.gov/25386609/) with the vitamin-fortified HNS formula. Those papers remain the core human evidence for wool-derived solubilized keratin. A 2010 company hair study is cited in trade writing but was not indexed as a full journal article. Later work shifted toward extensively hydrolyzed feather keratin (Kera-Diet / KeraGLO). Tursi and colleagues tested that hydrolysate without added vitamins, and a [2026 metabolite study](https://pubmed.ncbi.nlm.nih.gov/42221766/) measured a 20-minute amino-acid peak after a 5 g dose. Independent dermatology reviews now list solubilized keratin among oral nail ingredients while noting that manufacturers are not required to prove efficacy before sale. The current picture is not a settled consensus: it is a small, commercially generated evidence base with a newer, still commercial, hydrolysate arm. ## Expected Benefits ### Medium 🟩 🟩 #### Hair Strength, Shedding, and Luster In a 90-day [randomized, double-blind, placebo-controlled trial](https://pubmed.ncbi.nlm.nih.gov/25386609/), 50 women with damaged hair took 500 mg/day Cynatine HNS with added vitamins and minerals. Hair-pull loss fell 34.4% versus placebo, tensile strength rose 5.9%, the anagen/telogen (growth versus rest) ratio improved 9.2%, and dermatologist-scored luster rose 47.1% versus placebo. Roxlor LLC funded the trial and employed a co-author, so keratin is not isolated. A later [meta-analysis](https://pubmed.ncbi.nlm.nih.gov/41954038/) of mixed hair nutraceuticals that included this trial found lower telogen density across formulas. **Magnitude:** About one-third fewer hairs extracted on a pull test versus placebo at 90 days; 5.9% higher single-fiber tensile strength. #### Skin Moisture, Elasticity, and Wrinkle Appearance The matching 90-day [HNS trial in 50 women](https://pubmed.ncbi.nlm.nih.gov/23902431/) reported 11.1% more skin moisture versus a 19.3% fall on placebo, 12.2% more elasticity, and 11.5% less wrinkle depth. Roxlor funding and the vitamin mix apply here too. A 90-day [trial of 500 or 1,000 mg/day feather keratin hydrolysate](https://pubmed.ncbi.nlm.nih.gov/39367631/) without added vitamins found similar wrinkle and moisture changes, supporting a keratin-amino-acid effect beyond biotin and zinc. **Magnitude:** Roughly 11–17% more measured skin water and about 10–12% less wrinkle depth at 90 days versus baseline in the keratin arms. #### Nail Strength and Appearance In the same [HNS trial](https://pubmed.ncbi.nlm.nih.gov/25386609/), 87.5% of women on keratin improved nail breakage tendency versus 28.5% on placebo, and hard-nail ratings in the keratin arm rose from 37.5% to 87.5%. A [dermatology review](https://pubmed.ncbi.nlm.nih.gov/40176998/) lists solubilized keratin among oral nail ingredients. The HNS formula also contains biotin, which has its own brittle-nail literature, so the keratin-specific share is unknown. **Magnitude:** 87.5% of the keratin arm improved breakage tendency versus 28.5% on placebo at 90 days. ### Low 🟩 #### Knee Osteoarthritis Symptom Relief A 60-day [Roxlor-funded trial](https://pubmed.ncbi.nlm.nih.gov/23927594/) of 500 mg/day Cynatine FLX in 50 adults found 13% less WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain at six days versus 0.73% on placebo. By day 60 the groups no longer differed. **Magnitude:** 13% lower WOMAC pain at six days versus 0.73% on placebo; no significant between-group difference at 60 days. #### Lean Mass Versus Casein at Food-Protein Doses A four-week [crossover trial](https://pubmed.ncbi.nlm.nih.gov/30261892/) in 15 endurance-trained men compared 0.8 g/kg/day soluble feather keratin with casein. Bone-free lean mass rose 0.88 kg versus 0.07 kg on casein; cycling performance did not improve. The dose is far above the 500 mg appearance protocols. **Magnitude:** 0.81 kg more bone-free lean mass than casein over four weeks at 0.8 g/kg/day; no change in cycling performance. ### Speculative 🟨 #### Cellular Antioxidant Defense Cysteine from keratin can, in principle, support glutathione. Animal Cynatine work reported higher glutathione peroxidase and superoxide dismutase activity. Human trials did not measure those enzymes. The basis is mechanistic and preclinical only. #### Systemic Connective-Tissue Support With Age Trade writing frames hair, nail, and skin changes as windows on aging connective tissue. No trial has measured vascular, bone, or organ connective-tissue outcomes after oral solubilized keratin. The basis is mechanistic and anecdotal only. ## Benefit-Modifying Factors - **Sex:** The hair, skin, and nail trials enrolled only women. The osteoarthritis trial enrolled both sexes but did not publish a sex-stratified analysis. Whether men obtain the same appearance effects is untested. - **Baseline damage:** Beer excluded women whose nails already scored as non-brittle from the breakage analysis. Larger appearance gains are reported where hair, nails, or skin start damaged; already-robust tissue has less room to move. - **Baseline biomarkers:** No blood keratin, cysteine, or glutathione value has been shown to predict response. Enrollment used damaged hair, nails, or skin rather than a laboratory threshold. - **Age:** Enrolled adults were mostly 35–71 years. Keratin production in hair and epidermis slows with age, which is the usual rationale for use in older adults, but no dose-by-age analysis exists. - **Formula composition:** HNS products add biotin, zinc, copper, and B vitamins. People already replete in those micronutrients may see less of the composite effect; keratin-only products (FLX, Kera-Diet) remove that confound. - **Pre-existing joint disease:** The osteoarthritis signal, such as it is, was measured in symptomatic knee osteoarthritis, not in pain-free joints. Benefit in people without osteoarthritis is not shown. - **Genetics:** No polymorphism (a common gene variant) has been shown to change response to oral solubilized keratin. Rare keratin-gene disorders are a different clinical problem and are not a dosing guide. ## Potential Risks & Side Effects ### Low 🟥 #### Gastrointestinal Discomfort The HNS and FLX trials reported no adverse events. In the [99-woman hydrolysate trial](https://pubmed.ncbi.nlm.nih.gov/39367631/) some dropouts cited intestinal symptoms that authors blamed on seasonal illness. Oral protein hydrolysates can cause mild nausea or loose stool that typically stops when the product is stopped. **Magnitude:** Not quantified in available studies. Controlled trials did not publish a keratin-attributable gastrointestinal event rate. ### Speculative 🟨 #### Wool or Feather Protein Hypersensitivity Cynatine is sheep-wool protein; Kera-Diet is poultry feather. Wool or feather allergy is the theoretical group. [Indexed trials](https://pubmed.ncbi.nlm.nih.gov/25386609/) have not reported oral anaphylaxis (a sudden, severe allergic reaction). The basis is mechanistic only. #### Contaminants in Animal-Sourced Protein Wool and feather proteins could carry residual chemicals or mislabeled allergens. A blend recall involved undeclared fish protein in collagen, not keratin. The basis is mechanistic and from isolated reports only. #### Laboratory-Test Distortion From Fortified Formulas High-dose biotin in some HNS-style products can interfere with thyroid and troponin immunoassays (antibody-based lab tests). That risk is the biotin, not keratin. Keratin-only products do not carry it. ## Risk-Modifying Factors - **Known wool or feather allergy:** The main theoretical amplifier of hypersensitivity. People with occupational wool allergy or feather-bedding reactions are the group of concern; they were excluded from several trials. - **Baseline biomarkers:** No laboratory threshold identifies who will have gastrointestinal or allergic reactions. Prior wool or feather sensitization is the only practical screen. - **Gastrointestinal baseline:** Prior irritable-bowel symptoms or recent gastroenteritis (a stomach-and-intestine infection) may raise the chance that a hydrolysate is blamed for cramping or loose stool. - **Sex:** No sex-specific adverse-event pattern is published. Beauty trials were female-only, so male safety is inferred from the mixed osteoarthritis trial and the small male metabolite study. - **Age:** Older adults were included up to the early 70s with no excess-harm signal. Age-related kidney decline is unlikely to matter at 500 mg of protein, but that assumption is untested in advanced chronic kidney disease. - **Combination formulas:** Products that add high-dose biotin raise laboratory-interference risk. Products that add zinc and copper add those minerals’ own upper-limit issues if stacked with a multivitamin. ## Key Interactions & Contraindications - **High-dose biotin in HNS-style products (caution):** Can distort biotin-based thyroid and troponin assays. Hold the fortified product several days before such tests, or use a keratin-only formula. - **Stacked zinc and copper (monitor):** HNS capsules add both minerals. Extra zinc from a multivitamin can unbalance copper over time. Stay near typical dietary-supplement totals. - **Collagen peptides (additive, usually acceptable):** Overlapping amino-acid and skin-appearance targets. Combined use is common; expect overlapping rather than unique effects. - **Other sulfur amino acids — N-acetylcysteine, cystine (monitor):** Theoretical additive cysteine load. At 500 mg keratin the extra cysteine is small; no interaction trial exists. - **No established cytochrome-enzyme drug interactions:** Keratin peptides are digested as food protein, not handled by CYP3A4 (a major drug-metabolizing liver enzyme). Prescription-drug interactions of the enzyme-inhibitor type are not described. - **Over-the-counter pain relievers (none specific):** No pharmacokinetic interaction with ibuprofen or acetaminophen is described. Joint users sometimes take both; that is a symptom-stack, not a keratin interaction. **Populations who should avoid Solubilized Keratin:** - Known allergy to wool, lanolin, feathers, or labeled keratin (absolute contraindication; anaphylaxis risk is theoretical but untested orally) - Strict vegan or vegetarian dietary pattern if animal-sourced wool or feather protein is unacceptable (product identity, not toxicity) - Pregnancy or lactation (caution; these groups were excluded from the trials and no reproductive dataset exists) - Children and adolescents (not studied) - Advanced chronic kidney disease requiring protein restriction (caution; 500 mg is a small load, but no dedicated safety data) ## Risk Mitigation Strategies - **Choose keratin-only when isolating the ingredient:** FLX or a labeled hydrolysate avoids biotin-assay interference and vitamin confounds that complicate HNS products. - **Start at 500 mg with food:** Matches the Cynatine trial dose after breakfast and may limit gastrointestinal discomfort while remaining the lower hydrolysate dose that still moved skin measures. - **Hold fortified products before biotin-sensitive labs:** Stop HNS-style formulas several days before thyroid or troponin testing to prevent false assay results. - **Known wool or feather allergy:** Skipping the product eliminates the main theoretical hypersensitivity exposure. - **Salon keratin distinction:** Formaldehyde-releasing salon services are not oral solubilized keratin and carry a different inhalation-toxicity profile. - **Reassess at 90 days:** Appearance and joint trials ran 60–90 days. Stopping then if there is no perceptible change avoids continued exposure without a benefit. ## Therapeutic Protocol - **Usual studied dose:** 500 mg/day solubilized wool keratin (Cynatine). HNS trials used two capsules providing 500 mg keratin plus micronutrients. Feather hydrolysate was studied at 500 and 1,000 mg/day. - **Competing approaches:** Wool-derived solubilized keratin (Keraplast / Roxlor Cynatine) versus extensively hydrolyzed feather keratin (BCF Kera-Diet / KeraGLO). Neither is established as the default. - **Time of day:** HNS trials dosed both capsules in the morning after breakfast. The hydrolysate trial split four capsules between breakfast and dinner. - **Half-life:** Intact Cynatine peptide half-life is unpublished. After 5 g of feather hydrolysate, plasma amino acids peaked at about 20 minutes. - **Single versus split dose:** 500 mg wool keratin was given once daily. Split dosing was used only for the hydrolysate. No head-to-head absorption comparison exists. - **Genetics:** No APOE (lipid-transport gene), MTHFR (folate gene), or COMT (catecholamine gene) variant is known to change dose. - **Sex:** Appearance protocols are extrapolated from women-only trials. Joint dosing used mixed sexes at the same 500 mg. - **Age:** The same 500 mg was used from the mid-30s to early 70s. No age-based dose adjustment is published. - **Baseline biomarkers:** No blood keratin level guides dosing. More damaged hair, nails, or skin was the enrollment phenotype in the appearance trials. - **Pre-existing conditions:** Symptomatic knee osteoarthritis was the joint-trial population. Active scalp disease and recent hair-loss drugs were typical exclusions. ## Discontinuation & Cycling - **Duration of use:** Trials lasted 60–90 days (one completed hydrolysate hair trial planned 24 weeks). Lifelong use is not required by any dataset. - **Withdrawal:** No withdrawal syndrome is described. Keratin is not a receptor agonist with rebound physiology. - **Tapering:** Not applicable at 500–1,000 mg/day. Stopping without a taper is how the trials ended. - **Cycling:** No cycling protocol is published. If used for appearance, a 90-day on-period with a planned stop to judge persistence is the only schedule the trials support. - **Return of signs:** Hair, nail, and skin turnover continue after stopping. Any gain that depended on a daily amino-acid supply would be expected to fade over weeks to months; that fade has not been measured. ## Sourcing and Quality - **Identity of the protein:** Look for a named patented ingredient (Cynatine HNS or FLX; Functional Keratin; Kera-Diet / KeraGLO) rather than generic “keratin” of unknown molecular weight. - **Process type:** Solubilized wool keratin claims intact bioactivity and cystine. Hydrolyzed feather keratin is mostly free amino acids. They are related, not interchangeable, forms. - **Animal source:** Wool is *Ovis aries*; feather hydrolysate is poultry. A label that names the animal source supports allergy and diet screening. - **Third-party testing:** Independent identity and contaminant testing specific to keratin supplements is uncommon. NSF or USP seals, when present, usually cover the finished bottle, not keratin bioactivity. - **Reputable suppliers:** Keraplast (New Zealand wool) supplies Cynatine to Roxlor and finished-goods brands. BCF Life Sciences supplies Kera-Diet. Life Extension and similar catalog brands list Cynatine on some hair-skin-nail formulas. - **Avoid salon-treatment bottles:** Cosmetic keratin creams and formaldehyde-based straightening systems are not oral nutraceuticals. ## Practical Considerations - **Time to effect:** Hair-pull and nail scores moved by 30 days and further by 90. Skin moisture and elasticity moved by 30–45 days. Joint pain, when it moved, moved within six days and then lost its advantage by 60 days. - **Common pitfalls:** Treating this as a hair-loss drug equivalent to minoxidil or finasteride; buying a biotin-heavy blend and attributing every change to keratin; confusing oral keratin with formaldehyde salon treatments. - **Regulatory status:** Sold as a dietary supplement in the United States, not as an FDA-approved drug. Structure/function appearance claims do not require pre-market efficacy proof. - **Cost:** Typical 500 mg/day branded keratin is a mid-range specialty supplement, not an exceptional access barrier. Availability depends on the patented ingredient remaining in the finished product. ## Interaction with Foundational Habits - **Sleep:** Direct effect unknown. No trial reported insomnia or sedation. Indirectly, less joint pain at night could help sleep in the osteoarthritis phenotype; that pathway was not measured. - **Nutrition:** Direct, potentiating with dietary protein. Take with food as in the breakfast-dosed trials. A diet already rich in cysteine (eggs, whey) may shrink the incremental amino-acid gap the supplement is meant to fill. - **Exercise:** Indirect and possibly potentiating for joint users. The osteoarthritis trial did not prescribe or restrict training. No evidence that keratin blunts hypertrophy. Timing around workouts is unstudied. - **Stress management:** No direct cortisol data. The glutathione hypothesis is a stress-biology story without human endocrine endpoints. No technique variant is keratin-specific. ## Monitoring Protocol & Defining Success No blood test measures solubilized keratin. Baseline is a hair-pull (gentle traction on about 60 hairs in three scalp zones), photographs of hair part, nails, and crow’s-feet, and, if joints are the target, a simple pain and stiffness score. People using an HNS-style formula that includes high-dose biotin list that product on laboratory requisitions. Zinc and copper labs matter only when the bottle adds those minerals on top of a multivitamin. Repeat the hair-pull and photographs at 30 days, then again at 90 days. Joint users can score pain at one week and at 60 days, when the keratin-only trial no longer beat placebo. After 90 days, continued use tracks only if the pre-specified appearance or comfort change is still present. Success is change from the individual’s own baseline. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Hair-pull count | Fall from the person’s own baseline; conventional “positive” pull is often >9 hairs | Tracks shedding, the main hair endpoint in Beer 2014 | Do not wash hair for 2–3 days before the test; same three scalp zones each time | | Nail breakage / hardness score | Improvement from own baseline (Beer used a 1–4 improvement scale) | Captures the brittle-nail claim | Photograph the same nails in the same light; dermatologist grading is more reproducible than self-score | | Facial moisture / elasticity (device) | Rise from own baseline; no universal keratin target | Matches the skin-trial instruments | Measure after 15–20 min in a stable room; not a fasting blood test | | Serum zinc | Functional practice often targets mid-to-upper reference, about 90–120 µg/dL | Only if using zinc-fortified HNS or stacking zinc | Fasting morning draw; pair with copper if zinc intake is high | | Serum copper | Keep within the laboratory reference; watch the zinc:copper balance | Only if the formula or stack adds both minerals | Conventional reference is typically about 70–140 µg/dL; interpret with zinc | | Thyroid / troponin (if clinically required) | Assay-valid result, not a keratin target | Detect biotin interference from HNS-style products | Hold high-dose biotin several days before biotin-based immunoassays | Qualitative markers: - Daily shed hair in drain or brush, compared with the pre-start week - Nail splitting, peeling, or snagging on fabric - Subjective facial dryness, tightness, or makeup catch in crow’s-feet - Knee stiffness on first steps in the morning, if joints are the reason for use - Any new itch, hives, or gastrointestinal cramping in the first two weeks ## Emerging Research - **Completed 24-week hair trial, results not posted:** [NCT07458828](https://clinicaltrials.gov/study/NCT07458828) randomized 120 adults to 500 mg/day hydrolyzed keratin peptide or placebo for 24 weeks (Dong-A). A null result would weaken the 90-day Cynatine hair narrative. - **Metabolite and fibroblast study:** [Wauquier et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42221766/) gave 10 men 5 g Kera-Diet, found an amino-acid peak at about 20 minutes ([NCT06612866](https://clinicaltrials.gov/study/NCT06612866)), and reported higher fibroblast hyaluronan. Supports signaling, not a longevity endpoint. - **Mouse hair-regeneration work:** [Kim et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42187264/) reported that oral hydrolyzed keratin peptide pushed mouse follicles from rest into growth and activated β-catenin (a growth-signal protein). Human confirmation is the open question. - **Independent keratin-only beauty trials:** Alanazi et al., 2026 ([PMID 41954038](https://pubmed.ncbi.nlm.nih.gov/41954038/)) noted that most hair-nutraceutical trials, including Cynatine HNS, are industry-supported multi-ingredient formulas. A keratin-only, independently funded human trial would either strengthen or undercut the present case. - **Joint-structure endpoints:** The 2013 FLX trial ([PMID 23927594](https://pubmed.ncbi.nlm.nih.gov/23927594/)) used only symptom scores and lost its placebo-adjusted signal by day 60. Imaging or cartilage-marker work could weaken the joint claim further or revive it. ## Conclusion Solubilized keratin is a processed wool protein sold as a small daily oral dose. The case for using it rests on a handful of short randomized trials, almost all paid for by Roxlor LLC (Cynatine) or BCF Life Sciences (the feather-keratin product). Those trials report better hair-pull scores, greater hair luster, greater nail hardness, and moister, more elastic facial skin over about three months. A related feather-keratin amino-acid product, given without extra vitamins, showed similar skin and nail changes. Knee-pain scores moved early in one keratin-only trial and then caught up with placebo by two months. The main limits are size, length, and money. The best-known hair and skin product also contains biotin, zinc, copper, and B vitamins, so keratin is not isolated. Independent systematic work on this ingredient alone does not exist. A broader hair-supplement review that included it found modest shifts toward more growing hairs across many formulas. Reported harm in the trials was slight. Gastrointestinal symptoms appeared in a feather-keratin amino-acid study and may have had other causes. Wool or feather allergy is a reasonable theoretical concern and is untested in oral challenge studies. Combination products that add high-dose biotin can distort some laboratory tests; that problem is the biotin, not the keratin. For a longevity-oriented adult already investing in protein, sleep, and training, solubilized keratin is a narrow appearance-and-comfort intervention with a thin, commercially generated evidence base — not a lifespan therapy and not a proven joint-structure treatment. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**